NEW YORK (GenomeWeb News) – Life Technologies today announced that it has signed a research agreement and licensing deal with Harvard University focused on stem cell assays.
The firm said that it has acquired exclusive rights from Harvard to develop a panel of characterization assays designed to rapidly evaluate human pluripotent stem cells for their use in a variety of discovery and translational research applications. The panel is expected to be offered on Life Tech's Ion Torrent semiconductor sequencing platforms, as well as its PCR-based systems.